Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics

Journal of Clinical Psychopharmacology

Volumn 23, Issue 5, 2003, Pages 459-466

  Kirchheiner, Julia ^a   Müller, Gunnar ^a   Meineke, Ingolf ^b   Wernecke, Klaus Dieter ^a   Roots, Ivar ^a   Brockmöller, Jürgen ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DESIPRAMINE; TRIMIPRAMINE;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DEPRESSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME DEFICIENCY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; SLEEP PATTERN;

ADULT; AGED; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CONFIDENCE INTERVALS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; STATISTICS, NONPARAMETRIC; TRIMIPRAMINE;

EID: 0141705762     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000088909.24613.92     Document Type: Article

References (42)

1. Lapierre YD. A review of trimipramine. 30 years of clinical use. Drugs. 1989;38(suppl 1): 17-24; discussion 49-50.
2. Randrup A, Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology (Berl). 1977;53:309-314.
3. Hauser K, Olpe HR, Jones RS. Trimipramine, a tricyclic antidepressant exerting atypical actions on the central noradrenergic system. Eur J Pharmacol. 1985;111:23-30.
4. Waldmeier PC. Effects of antidepressant drugs on dopamine uptake and metabolism. J Pharm Pharmacol. 1982;34:391-394.
5. Gross G, Xin X, Gastpar M. Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacology. 1991;30:1159-1166.
6. Steiger A, von Bardeleben U, Guldner J, et al. The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:125-137.
7. Hohagen F, Montero RF, Weiss E, et al. Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci. 1994;244:65-72.
8. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984;230:94-102.
9. Petersen RC, Richelson E. Anticholinergic activity of imipramine and some analogs at muscarinic receptors of cultured mouse neuroblastoma cells. Psychopharmacology (Berl). 1982;76:26-28.
10. Cohn JB, Wilcox CS, Goodman LI. Antidepressant efficacy and cardiac safety of trimipramine in patients with mild heart disease. Clin Ther. 1993;15:114-126.
11. Suckow RF, Cooper TB. Determination of trimipramine and metabolites in plasma by liquid chromatography with electrochemical detection. J Pharm Sci. 1984;73:1745-1748.
12. Moffat AC, Jackson JV, Widdop B. Clarke's Isolation and Identification of Drugs. 2nd ed. London: Pharmaceutical Press; 1986.
13. Mellström B, Säwe J, Bertilsson L, et al. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther. 1986;39:369-371.
14. Mellström B, Bertilsson L, Säwe J, et al. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther. 1981;30:189-193.
15. Nielsen KK, Brøsen K, Gram LF. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. Eur J Clin Pharmacol. 1992;43:405-411.
16. Madsen H, Nielsen KK, Brøsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms - a population study. Br J Clin Pharmacol. 1995;39:433-439.
17. Spina E, Gitto C, Avenoso A, et al. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol. 1997;51:395-398.
18. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998;38:112-121.
19. Brøsen K, Gram LF. Pharmacokinetic and clinical significance of genetic variability in psychotropic drug metabolism. Psychopharmacol Ser. 1989;7:192-200.
20. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173-192.
21. Bolaji OO, Coutts RT, Baker GB. Metabolism of trimipramine in vitro by human CYP2D6 isozyme. Res Commun Chem Pathol Pharmacol. 1993;82:111-120.
22. Eap CB, Laurian S, Souche A, et al. Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. Neuropsychobiology. 1992;25:214-220.
23. Leinonen E, Koponen HJ, Lepola U. Paroxetine increases serum trimipramine concentration. A report of two cases. Hum Psychopharmacol. 1995;10:345-347.
24. Baumann P, Jonzier-Perey M, Koeb L, et al. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol. 1986;1:102-112.
25. Skjelbo E, Gram LF, Brøsen K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. Br J Clin Pharmacol. 1993;35:331-334.
26. Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol. 2001;41:1043-1054.
27. Seifritz E, Holsboer-Trachsler E, Hemmeter U, et al. Increased trimipramine plasma levels during fluvoxamine comedication. Eur Neuropsychopharmacol. 1994;4:15-20.
28. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45:1211-1214.
29. Eap CB, Bender S, Gastpar M, et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2CI9- and CYP3A4/5-phenotyped patients. Ther Drug Monit. 2000;22:209-214.
30. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6:341-349.
31. Musa MN. Nonlinear kinetics of trimipramine in depressed patients. J Clin Pharmacol. 1989;29:746-747.
32. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
33. Sachse C, Brockmöller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences [see comments]. Am J Hum Genet. 1997;60:284-295.
34. Boeckmann A, Sheiner L, Beal S. NONMEM User's Guide. San Francisco, CA: University of California, San Francisco; 1994.
35. Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl. 1997;391:14-21.
36. König F, Wolfersdorf M, Loble M, et al. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression. Pharmacopsychiatry. 1997;30:125-127.
37. Musshoff F, Schmidt P, Madea B. Fatality caused by a combined trimipramine-citalopram intoxication. Forensic Sci Int. 1999;106:125-131.
38. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther. 1986;40:543-549.
39. Madsen H, Hansen TS, Brøsen K. Imipramine metabolism in relation to the sparteine oxidation polymorphism - a family study. Pharmacogenetics. 1996;6:513-519.
40. Madsen H, Rasmussen BB, Brøsen K. Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 1997;61:319-324.
41. Koyama E, Tanaka T, Chiba K, et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4′ -hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol. 1996;16:286-293.
42. Abernethy DR, Greenblatt DJ, Shader RI. Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. Clin Pharmacol Ther. 1984;35:348-353.